UOC
CLSD

UBS O'Connor’s Clearside Biomedical CLSD Stock Holding History

UBS O'Connor’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-6,583
Closed -$1.06M – 283
2018
Q1 		$1.06M Buy
+6,583
New +$802K 0.02% 225

Other funds holding CLSD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
NC
Northpointe Capital Bloomfield Hills, Michigan $258M AUM 1.97% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

UBS O'Connor's CLSD Position: Q2 2018 in Review

UBS O'Connor sold out of Clearside Biomedical (CLSD) in Q2 2018, closing a stake of 6,583 shares — an estimated $1.06M sold.

UBS O'Connor first reported a position in CLSD in Q1 2018 and held it in 1 quarter. The position peaked at $1.06M in Q1 2018. 86 funds tracked by Wall St. Rank hold CLSD as of Q2 2018.

  • UBS O'Connor reported no remaining Clearside Biomedical position as of Q2 2018 after selling out during the quarter.
  • UBS O'Connor sold 6,583 Clearside Biomedical shares in Q2 2018, an estimated $1.06M.
  • UBS O'Connor first reported a position in Clearside Biomedical in Q1 2018 and held it in 1 quarter.
  • UBS O'Connor's Clearside Biomedical position peaked at $1.06M in Q1 2018.
  • 86 funds tracked by Wall St. Rank held Clearside Biomedical as of Q2 2018.

Based on UBS O'Connor's 13F filing for Q2 2018, filed 14 Aug 2018.